---
title: "The public offering of HANXBIO-B was oversubscribed by 3,073 times, with a 1% chance of winning one lot"
description: "HANXBIO-B's public offering was oversubscribed by 3,073 times, with a one-hand allotment rate of 1%. The international offering recorded a subscription of 5.78 times, with a final offer price of HKD 3"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/270511477.md"
published_at: "2025-12-22T15:21:53.000Z"
---

# The public offering of HANXBIO-B was oversubscribed by 3,073 times, with a 1% chance of winning one lot

> HANXBIO-B's public offering was oversubscribed by 3,073 times, with a one-hand allotment rate of 1%. The international offering recorded a subscription of 5.78 times, with a final offer price of HKD 32, raising a net amount of HKD 531 million. Shares are expected to be listed on Tuesday, with seven cornerstone investors collectively subscribing to 2.9178 million shares, accounting for 15.93% of the total offering

HANXBIO-B (03378.HK) announced the results of its IPO, with the Hong Kong public offering receiving 3,074.09 times subscription, and a 1% chance of winning for one board lot (100 shares), with a subscription of 600,000 shares needed to secure one lot. The international offering recorded 5.78 times subscription. The final offer price is HKD 32, at the upper limit, raising a net amount of HKD 531 million. The shares are expected to be listed on Tuesday (23rd).

The biotechnology company HANXBIO plans to globally offer 18.321 million shares, with 10% allocated for public offering. The offer price ranges from HKD 28 to HKD 32. Seven cornerstone investors, including Fudex Resources Investment, Sage Partners Master Fund, Guotai Junan Securities Investment, TFI Investment Fund SPC, Main Source Capital, YStem Holding, and Chunlei Capital, subscribed a total of 2.9178 million shares, accounting for 15.93% of the total offering. The final date for the lock-up commitment is June 22, 2026

### Related Stocks

- [03378.HK - HANXBIO-B](https://longbridge.com/en/quote/03378.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hanx Biopharmaceuticals Sets Out Board and Committee Structure | Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has announced its board composition, led by chairman Dr. Zhang Faming, includin | [Link](https://longbridge.com/en/news/275228301.md) |
| Hanx Biopharmaceuticals Files Director List with HKEX | Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has submitted an updated director list to the Hong Kong Stock Exchange. The Boa | [Link](https://longbridge.com/en/news/275224008.md) |
| Westfuller Advisors LLC Has $5.96 Million Stake in NVIDIA Corporation $NVDA | Westfuller Advisors LLC increased its stake in NVIDIA Corporation (NASDAQ: NVDA) by 33.8% in Q3, now holding 31,955 shar | [Link](https://longbridge.com/en/news/275977152.md) |
| Zelenskiy says US too often asks Ukraine, not Russia, for concessions | Ukrainian President Volodymyr Zelenskiy expressed concerns that U.S.-brokered peace talks may unfairly focus on concessi | [Link](https://longbridge.com/en/news/275977683.md) |
| 12:04 ETMelissa & Doug Founders Inducted into Toy Hall of Fame as Brand's Commitment to Purposeful Play Takes Center Stage at Toy Fair® 2026 | Doug and Melissa Bernstein, founders of Melissa & Doug®, were inducted into the Toy Industry Hall of Fame at the 2026 To | [Link](https://longbridge.com/en/news/275984858.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.